SCHEMBL1482215

SCHEMBL1482215

Brc1ccccc1-c1nc2ccccc2n1CCC1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
RXRG P48443 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
LMNA P02545 1/20 0.49
TSHR P16473 1/20 0.49
HTT P42858 1/20 0.49
BRD4 O60885 1/20 0.47
BAZ2A Q9UIF9 1/20 0.47
MAPT P10636 3/20 0.45
TP53 P04637 2/20 0.45
HPGD P15428 1/20 0.43
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482899 0.88 PRKACA (0.53) NPSR1TSHRHTTBRD4BAZ2A
SCHEMBL1482023 0.77 RXRA (0.43) RXRARXRBRXRGNPSR1LMNA
SCHEMBL1482134 0.77 RXRA (0.43) RXRARXRBRXRGNPSR1LMNA
SCHEMBL1482425 0.76 PRKACA (0.50) NPSR1LMNATSHRHTTBRD4
SCHEMBL6810630 0.76 TLR8 (0.57) LMNATSHRHTTMAPTTP53
SCHEMBL1577111 0.75 KCNH2 (0.44) RXRARXRBRXRGNPSR1LMNA
SCHEMBL1482155 0.74 ALOX5 (0.52) NPSR1BRD4BAZ2AHDAC3HDAC1
SCHEMBL30581236 0.74 KDM4E (0.60) NPSR1LMNATSHRHTTMAPT
SCHEMBL29076126 0.74 KDM4E (0.60) NPSR1LMNATSHRHTTMAPT
SCHEMBL1482795 0.74 PRKACA (0.46) LMNATSHRHTTBRD4BAZ2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 RXRA 1486/4885RXRB 1126/4885RXRG 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.